en
svPress releases
Regulatory press release 2023-12-01
Xspray Pharma raises SEK 92.3 million through warrants TO5
Press release 2023-11-21
Xspray Pharma’s XS003 Achieves Superior Bioavailability Milestone, Matching TASIGNA® at Reduced Dosage
Press release 2023-11-16
Important information to holders of warrants series TO5: The subscription period is ongoing
Regulatory press release 2023-11-09
Xspray Pharma’s large shareholders and key individuals declare their intent to exercise TO5 warrants in November
Regulatory press release 2023-11-08
Interim Report Third Quarter 2023
Press release 2023-10-26
Xspray Publication Demonstrates High Concomitant PPI and TKI Use in CML Resulting in Risk of Increased Mortality Which May be Mitigated by DASYNOC™
Regulatory press release 2023-10-24
Xspray Pharma’s Nomination Committee for the Annual General Meeting 2024
Press release 2023-09-15
Xspray Pharma appoints Chief Commercial Officer to drive upcoming Dasynoc™ US product commercialization
Regulatory press release 2023-09-11
Xspray Pharma and Bristol Myers Squibb Reach Settlement on Dasynoc™ Patent Litigation, Paving Way for Early Market Launch
Regulatory press release 2023-08-02